IRCT20200407046981N44 IRCT 2022-10-19 Vana Darou Gostar Pharmaceutical Company Study of absorption and elimination rate of Biperiden 4-mg extended-release tablets in comparison with Biperiden brand tablets (Akineton®) Comparative bioequivalence study of the Biperiden 4-mg extended-release tablets manufactured by Vana Darou Gostar Pharmaceutical Company versus Akineton® (Desma Company) 2022-10-30 anticipated 24 Complete https://irct.ir/trial/66351 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: To randomly assign people in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope after entering the study, and numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of the both groups will change for the second period. Bioequivalence Bioequivalence study. Intervention 1: Intervention group1: In this group, volunteers are given a single oral dose of the Biperiden 4-mg extended-release tablets produced by Vana Darou Gostar Co. (Domestic). In each period, 12 of 24 subjects will be given single oral dose of this product. After the washout period, the volunteers are placed in the Intervention group 2. Intervention 2: Intervention group2: In this group, volunteers are given a single oral dose of Biperiden 4-mg extended-release tablets (Akineton®), produced by Desma Company (Brand). In each period, 12 of 24 subjects will be given single oral dose of this product. After the washout period, the volunteers are placed in the Intervention group 1. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information